Stable oral suspensions of baclofen
The present invention relates to stable liquid pharmaceutical compositions of baclofen or a pharmaceutically acceptable salt thereof. More specifically, stable oral suspensions of baclofen at concentrations of equal to or more than 2 mg/mL or more are provided. Preferably, the liquid pharmaceutical compositions of baclofen are suitable for oral administration and are stable at wider pH ranges over a variety of storage conditions, including long-term storage for extended periods of time. Methods of treating various disorders using the inventive pharmaceutical compositions are also provided. The invention further relates to various methods for preparing stable suspension of baclofen.
1 . A stable liquid suspension comprising:
a. about 5 mg/mL of baclofen;
b. at least one stabilizer; and
c. at least one pharmaceutically acceptable liquid vehicle;
wherein the suspension is in the form of a ready-to-use liquid suspension or a ready-to-administer liquid suspension that is suitable for oral administration to a subject in need thereof, and
wherein no crystal growth is observed when suspension was stored for 3 months at 40° C./75% RH.
2 . The suspension according to claim 1 , further comprising one or more pharmaceutically acceptable excipients selected from the group consisting of pH adjusting agents, buffering agents, solubilizers, suspending agents, antioxidants, anti-foaming agents, chelating agents, preservatives, flavoring agents, sweetening agents, coloring agents, surfactants, and mixtures thereof.
3 . The suspension according to claim 2 , wherein the one or more pharmaceutically acceptable excipients comprise an anti-foaming agent, and further wherein the antifoaming agent is a simethicone emulsion.
4 . The suspension according to claim 1 , wherein the suspension is an aqueous suspension.
5 . The suspension according to claim 1 , wherein the suspension has a pH between about 4 to about 8.
6 . A method for managing, treating, or alleviating the signs and symptoms of spasticity resulting from multiple sclerosis, spinal cord damage or spinal cord disease in a patient in need thereof by orally administering a therapeutically effective amount of the suspension according to claim 1 .
7 . The method of claim 6 , wherein the patient is a pediatric patient or a geriatric patient.
8 . The suspension according to claim 1 , wherein the stabilizer is selected from the group consisting of hydroxypropyl methylcellulose (HPMC), hydroxypropyl cellulose (HPC), povidone (PVP K-30), poloxamer and mixtures thereof.